Human papillomavirus vaccine uptake in adolescence and adherence to cervical cancer screening in Switzerland: a national cross-sectional survey.

Objectives: The objectives were to measure uptake of and factors associated with human papillomavirus (HPV) vaccination initiation and to determine whether HPV vaccination reduced the uptake of cervical cancer screening.

Methods: We conducted a cross-sectional survey in a random sample of Swiss women aged 18-49 years in 2014 (N = 3588).

Results: Vaccination initiation was 69.

The public health value of vaccines beyond efficacy: methods, measures and outcomes.

Background: Assessments of vaccine efficacy and safety capture only the minimum information needed for regulatory approval, rather than the full public health value of vaccines. Vaccine efficacy provides a measure of proportionate disease reduction, is usually limited to etiologically confirmed disease, and focuses on the direct protection of the vaccinated individual. Herein, we propose a broader scope of methods, measures and outcomes to evaluate the effectiveness and public health impact to be considered for evidence-informed policymaking in both pre- and post-licensure stages.

The Federal Vaccination Commission in Switzerland: an officially appointed independent commission ensuring evidence-based recommendations and transparent procedures.

The Commission Fédérale pour les Vaccinations (CFV; Federal Vaccination Commission), the Swiss National Immunization Technical Advisory Group (NITAG), was established in 2004 and is comprised of 15 core members and a few ex officio members. Its role is to serve as a scientific advisor to the authorities in making vaccination recommendations, and to act as a mediator between the authorities, experts, and the public on questions concerning vaccinations. The CFV requires all members to describe in detail any potential conflicts of interest.

Little evidence that hepatitis C virus leads to a higher risk of mortality in the absence of cirrhosis and excess alcohol intake: the Swiss Hepatitis C Cohort Study.

The objective of this study was to describe the all-cause mortality of participants in the Swiss Hepatitis C Cohort compared to the Swiss general population. Patients with hepatitis C virus (HCV) infection attending secondary and tertiary care centres in Switzerland. One thousand six hundred and forty-five patients with HCV infection were followed up for a mean of over 2 years.